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Abstract
As one of the most widely used drugs worldwide, heparin is an 
essential anticoagulant required for surgery, dialysis, treatment 
of thrombosis, cancer, and general circulatory management. Sta-
bilin-2 is a scavenger clearance receptor with high expression 
in the sinusoidal endothelium of liver. It is believed that Stabi-
lin-2 is the primary receptor for the clearance of unfractionated 
and low molecular weight heparins in the liver. Here, we iden-
tify the modifications and length of the heparin polymer that are 
required for binding and endocytosis by both human Stabilin re-
ceptors: Stabilin-2 and its homolog Stabilin-1 (also found in liver 
endothelium). Using enzymatically synthesized 35S-labeled hep-
aran sulfate oligomers, we identified that sulfation of the 3-OH 
position of N-sulfated glucosamine (GlcNS) is the most benefi-
cial modification for binding and endocytosis via both Stabilin 
receptors. In addition, our data suggest that a decasaccharide 
is the minimal size for binding to the Stabilin receptors. These 
findings define the physical parameters of the heparin structure 
required for efficient clearance from blood circulation. These re-
sults will also aid in the design of synthetic heparins with de-
sired clearance rates. 
Keywords: Endocytosis, Endothelial Cell, Heparan Sulfate, Hep-
arin, Receptors, Arixtra, Stabilin, Glycosaminoglycan, Liver
Abbreviations: UFH, unfractionated heparin; HARE, hyaluronic 
acid receptor for endocytosis; HS, heparan sulfate; CS, chon-
droitin sulfate; Stab1, Stabilin-1; Stab2, Stabilin-2; LMWH, low 
molecular weight heparin; IdoA, iduronic acid; PAPS, 3′-phos-
phoadenosine 5′-phosphosulfate; OST, sulfotransferase; ATIII, 
antithrombin III; ESI, electrospray ionization; AnMan, 2,5-Anhy-
dromannitol; GlcNTFA, N-trifluoroacetylated glucosamine; NST, 
N-sulfotransferase. 
Heparin is an anticoagulant drug that is widely prescribed 
for procedures in which blood is handled, including sur-
gery, blood/plasma donation, coronary and peripheral vascu-
lar procedures, thrombosis, dialysis, and in the washing and 
preparation of medical equipment (1). The current supply of 
heparin is derived from the pulp of porcine small intestine and 
is harvested as unfractionated heparin (UFH)3 with polymeric 
chain lengths ranging from 3,000 to 30,000 Da. UFH is depo-
lymerized into smaller sizes with chain lengths ranging from 
2000 to 8000 Da to yield the products known as low molecular 
weight heparin (LMWH). Generally, both UFH and LMWH 
are fast-acting coagulants with different clearance rates. UFH 
has a circulatory half-life of 30–60 min, in contrast to LMWH, 
which has a half-life of 2–6 h (2, 3). 
The clearance of heparin is primarily mediated by liver si-
nusoidal endothelial cells (4). The primary receptor responsi-
ble for the systemic clearance of heparin is Stabilin-2/HARE 
(Stab2)(HARE, hyaluronic acid receptor for endocytosis) (5, 6). 
Thus, the binding affinity of heparin to Stab2 likely relates to 
the clearance rate of heparin. Stab2 is presented on the cell sur-
face as two isoforms: 315- and 190-kDa type I receptors. A sub-
set of the 315-kDa receptor undergoes proteolytic cleavage to 
produce the smaller 190-kDa receptor. Both 315-kDa and 190-
kDa Stab2 receptors bind to and participate in systemic clear-
ance of heparin (7, 8). The binding affinity of Stab2 to UFH 
is higher than LMWH, suggesting that interactions between 
Stab2 and heparin are dependent on the length of the polymer. 
Stab2 receptors are also responsible for clearing other glycos-
aminoglycans, including hyaluronic acid and chondroitin sul-
fates. It is known that the Stab2 binding domain(s) for heparin 
are distinct from the Link domain for binding hyaluronic acid 
and chondroitin sulfates (9). 
Stabilin-1 (Stab1) is a Stab2 homologous protein expressed 
in humans, which has not been reported to bind to heparin 
previously. The topological organization of Stab1 is similar to 
Stab2 in that they share 21 EGF/EGF-like domains, seven Fas-
ciclin-1 domains, and one X-link domain with an overall 41% 
amino acid identity and 56% similarity. Stab1, like Stab2, is ex-
pressed in the endothelium of liver, lymph node, and spleen, 
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but is also uniquely expressed in activated macrophages and 
continuous endothelial vasculature (10, 11), suggesting that 
this receptor is immune-responsive. Both Stab1 and Stab2 bind 
an array of ligands. Stab1 binds to SPARC (secreted protein 
acidic and rich in cysteine) (12) and lactogen (13); Stab2 binds 
to collagen propeptides (6) in addition to glycosaminoglycans. 
The common ligands for both receptors are acetylated LDL (5, 
14), GDF-15 (15), phosphatidylserine (16–18), and advanced 
glycation end products (19). 
Heparan sulfate (HS) is a glycosaminoglycan consisting 
of repeating disaccharide units of glucuronic acid (GlcA) or 
iduronic acid (IdoA) and glucosamine, with each of the sac-
charide units capable of carrying sulfo groups. The positions 
of the sulfo groups, the location of the IdoA residues, and the 
size of the HS chain determine its biological functions. Hepa-
rin is a special form of HS, carrying higher levels of sulfation 
and IdoA. HS is a highly heterogeneous complex mixture. 
Its biosynthesis involves the preparation of a polysaccharide 
backbone and a series of sulfations and epimerization modi-
fications. The enzymes that carry out these modification re-
actions have been expressed and purified (20). Utilizing re-
combinant HS biosynthetic enzymes, we demonstrated the 
synthesis of HS polysaccharides with specific sulfation pat-
terns (21, 22) and HS oligosaccharides with defined struc-
tures (23, 24). The synthesized polysaccharides and oligo-
saccharides act as valuable reagents to probe the structural 
selectivity of HS in a given biological or biochemical experi-
ment (20, 24). 
In this study, we used synthetic HS polysaccharides and 
oligosaccharides to probe the structural requirements for bind-
ing to the Stabilin receptors. We report that 3-O-sulfation has 
a significant impact on binding/endocytosis. The size of poly-
mer also plays a role in endocytosis. We describe the mini-
mal size and sulfations required for endocytosis in recombi-
nant cell lines and in murine liver endothelium. For the first 
time, we demonstrate that Stab1 is also responsible for the in-
ternalization of heparin in cell culture and in binding assays 
performed in vitro. Our findings advance the understanding of 
the mechanism for clearing HS and heparin. Our results also 
provide a molecular basis for designing heparin anticoagulant 
drugs with different clearance rates. 
Experimental Procedures
Materials, Solutions, and Buffers — Heparin (or unfrac-
tionated heparin) was from Sigma. Fondaparinux (Arixtra®) 
was purchased from a local pharmacy. Flp-In 293 cells, serum, 
high glucose Dulbecco’s modified Eagle’s medium (DMEM), 
Hygromycin B, Zeocin, and glutamine were from Invitrogen. 
Western blot analysis was completed by either colorimetric or 
chemiluminescence detection of blotted protein. Anti-V5 anti-
bodies and resins were from Bethyl Laboratories (Montgom-
ery, TX). Other materials, reagents, and kits were obtained 
as described recently (9). Tris-buffered saline with Tween 20 
(TBST) contains 20 mm Tris-HCl, pH 7.0, 150 mm NaCl, and 
0.1% Tween 20. TBST/BSA is TBST with 1.0% (w/v) bovine 
serum albumin (BSA). Phosphate-buffered saline (PBS) con-
tains 137 mm NaCl, 8 mm Na2HPO4, 1.5 mm KH2PO4, 2.7 mm 
KCl, pH 7.2. Hanks’ buffered saline solution contains 5 mm 
KCl, 0.4 mm KH2PO4, 0.8 mm MgSO4, 137 mm NaCl, 0.3 mm 
Na2HPO4, 5.5 mm glucose, 1.26 mm CaCl2, 0.5 mm MgCl2, and 
28 μm phenol red; at the time of use, 3.5 g/100 ml of NaHCO3 
was added, and the pH was adjusted to 7.2 with HCl. Endocy-
tosis Medium contains DMEM supplemented with 0.05% BSA. 
Figure 1. Chemical structures of different HS constructs. A, the general structure of all 10 different constructs. The top left structure shows the struc-
tures of those constructs without iduronic acid residues. The top right structure shows the structures of those constructs with iduronic acid residues. 
Each individual polysaccharide construct is shown in the table underneath those two generic structures. B, the structure of a decasaccharide (10-mer, 
15b) that displays full binding ability to the Stabilin receptors as described under “Results.” To maintain clarity, the structures of other oligosaccharide 
constructs are not shown. The abbreviated structures are listed in Table 1. 
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Preparation of 35S-labeled HS Constructs — A total of 27 
HS constructs were prepared for this study using a chemo-
enzymatic approach published previously (Figure 1 and Ta-
ble 1) (22, 24). Constructs 1 through 10 (Figure 1A) are poly-
saccharide constructs differing in sulfation types and IdoA 
content, whereas constructs 11 through 23 are oligosaccha-
ride constructs ranging from hepta- to nonadecasaccharides. 
A representative structure of a decasaccharide (15b) is shown 
in Figure 1B. For the synthesis of polysaccharide constructs (1 
through 10), N-sulfo heparosan was used as a starting mate-
rial and incubated with the appropriate enzymes and the sulfo 
donor 3′-phosphoadenosine 5′-phosphosulfate (PAPS) (22). 
The polysaccharide products were analyzed by disaccharide 
analysis to confirm the anticipated sulfations (25). To prepare 
the oligosaccharide constructs (11 through 23), both elonga-
tion and modification steps were involved. During the elonga-
tion step, a disaccharide starting material (GlcA-AnMan) was 
first elongated to the desirable size with KfiA (N-acetyl glu-
cosaminyl transferase of Escherichia coli K5 strain) and pmHS2 
(Pasteurella multocida heparosan synthase 2) in the presence 
of UDP-GlcA and UDP-GlcNAc or UDP-GlcNTFA. The elon-
gated products were confirmed by electrospray ionization 
mass spectrometry (ESI-MS). The oligosaccharides were then 
converted to N-sulfo oligosaccharides by treating with tri-
ethylamine followed by N-sulfotransferase modification. The 
products were demonstrated to have the anticipated molecu-
lar size and purity by ESI-MS. The ESI-MS spectra of the octa- 
to decasaccharides are shown in Supplemental Figure S1. For 
those oligosaccharides larger than dodecasaccharides, the ESI-
MS spectra are shown in separate publications (23).*
The oligosaccharides were then modified by C5-epimerase, 
2-O-sulfotransferase (2-OST), 6-O-sulfotransferase 1 and 3 (6-
OST-1 and 6-OST-3), and 3-O-sulfotransferase 1 (3-OST-1). Af-
ter the modifications, a mixture of oligosaccharides with dif-
ferent levels of sulfation was obtained as determined by DEAE 
(diethylaminoethyl)-HPLC (Supplemental Figure S2). To in-
troduce a 35S label to the polysaccharides or oligosaccharides, 
[35S]PAPS replaced unlabeled PAPS. 35S-labeled 3-O-sulfated 
heparin was prepared by incubating heparin with 3-OST-5 en-
zyme and [35S]PAPS, and the product was purified by DEAE 
chromatography. 
The procedures for preparing the N-sulfo heparosan, PAPS 
and [35S]PAPS, UDP-GlcNTFA, and disaccharide (GlcA-An-
Man) starting materials are described elsewhere (22, 23, 27). 
The enzymes used for the synthesis, including KfiA, pmHS2, 
NST, C5-epimerase, 2-OST, 6-OST-1, 6-OST-3, and 3-OST-1, 
were expressed in E. coli as described previously (24). 
Expression Plasmids — The cDNA for human Stab1 (a 
kind gift of J. Kzhyshkowska, University of Heidelberg) and 
Stab2/315-HARE were ligated into the multi-cloning site of 
the pcDNA5/FRT/V5-6×HIS-TOPO vector. The Stab2/190-
HARE cDNA encoding the C-terminal 1416 amino acids is 
cloned in pSecTag/FRT/V5–6×HIS-TOPO, which provides a 
secretion signal for the 190-HARE protein (8). Plasmids encod-
ing the secreted ectodomain were generated by single primer 
deletion mutagenesis (7) in which the transmembrane and cy-
toplasmic domain encoding regions were deleted, and the re-
sulting plasmids were then used to create stable cells that se-
creted properly folded and functional ectodomains in the 
medium. The ectodomains comprised amino acids M1-P2475 
for Stab1, M1-T2458 for Stabilin-2/315-HARE, and S1136-
V2453 for Stab2/190-HARE. 
Endocytosis Assays — Stably transfected cells expressing 
Stab1 or Stab2 receptors or only Hygromycin B-resistant (empty 
vector) were plated in 24-well dishes and grown in DMEM with 
8% FBS and 50 μg/ml Hygromycin B for at least 2 days prior to 
the experiments. The cells were incubated at 37 °C for 3 h with 
fresh Endocytosis Medium supplemented with labeled [35S]HS 
constructs (2.0 × 104 cpm/ml). For those experiments utilizing 
antithrombin III (ATIII), the [35S]HS constructs were preincu-
bated with ATIII (0.2 mg/ml) for 30 min prior to diluting 10-
fold in endocytosis medium. Specific binding or endocytosis 
was assessed in the presence of excess unlabeled heparin (0.1 
mg/ml) to determine background count per minute (cpm) val-
ues. These values were subtracted from all data points to de-
termine the specific [35S]HS endocytosis. At the termination 
times, cells were washed three times with ice-cold Hanks’ buff-
ered saline solution and lysed in 0.3 n NaOH, and radioactivity 
and protein content were determined and expressed as cpm/
μg of protein ± S.D. 35S radioactivity of all samples was mea-
sured by a Beckman-Coulter LS6500 scintillation counter. Non-
specific binding/background radiation levels were consistently 
between 16 and 20 cpm for all experiments. 
Direct Binding Assays — To assess direct protein-HS bind-
ing, ectodomains of each receptor were expressed and secreted 
in stable cell lines. The ectodomains were immunoprecipitated 
with a goat anti-V5 resin (Bethyl Laboratories), washed with 
TBS, and then incubated with 4.0 × 105 cpm of each [35S]HS 
construct for 1.5 h under rotation. The resin was centrifuged, 
washed three times with TBS, and then placed in scintillation 
fluid and quantified by a Beckman-Coulter LS6500 scintilla-
tion counter. The amount of protein on the resin was quanti-
fied by separation with 5% SDS-PAGE, blotted, and probed 
with rabbit anti-V5 antibody (Bethyl Laboratories), and im-
ages were captured on film. 
Assessment of Liver Clearance — All animal procedures 
were approved by the Institutional Animal Care and Use Com-
mittee (IACUC) of the University of Nebraska under the Asso-
ciation for Assessment and Accreditation of Laboratory Animal 
Care (AAALAC) guidelines. BALB/c mice were placed under 
general anesthesia (isoflurane) on a warming platform during 
the entire procedure. Once unconsciousness was confirmed, the 
mice were injected via the lateral tail vein using a 27-gauge × 
1/2 inch needle with 0.053 μCi of 35S-labeled HS construct. The 
radiolabeled material was allowed to circulate for 10 min fol-
lowed by abdominal exposure and severance of the descending 
aorta abdominalis for bleed out. The liver was collected, briefly 
washed to get rid of residual blood, cut into smaller (~0.1 g) 
pieces, weighed, and then homogenized with a PowerGen 125 
(Fisher) tissue homogenizer in 0.75 ml of 1% Nonidet P-40. Ho-
mogenized tissue was then spun at 12,000 × g for 2 min to clear 
out insoluble material, and supernatants were mixed with 4 ml 
of scintillation fluid and counted. 
Results
35S-labeled Heparin Binds Stabilin-1 and Stabilin-2 Re-
ceptors — Cell lines stably expressing Stab2 and empty vector 
were created as described previously (7, 8). The cell line sta-
bly expressing human Stab1 cDNA was also constructed with 
identical methodology. The expressions of Stab1 and Stab2 
are shown by a representative Western blot of the cell lysates 
* Y. Xu, E. H. Pempe, and J. Liu, submitted for publication. 
Structural Selectiv ity of Synthetic heparin Binding to StaBil in protein receptorS   20777
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
probed with the anti-V5 antibody (Figure 2A). The expression 
of the recombinant receptors is similar to the native receptors 
in that a percentage of the full-length Stab2 is processed to the 
smaller 190-kDa isoform and Stab1 is expressed as a tight dou-
blet at around 323 kDa. The level of expression for 315-HARE 
Stab2 is less than that of 190-HARE Stab2 in the recombinant 
cell lines; thus, the HS binding values for the 315-HARE cell 
line are typically lower. 
35S-labeled heparin was used as a positive control to assess 
binding and endocytosis throughout the study. The 35S-la-
beled heparin (or 35S-labeled 3-O-sulfated heparin) was spe-
cifically labeled at the 3-OH position by incubating heparin 
with 3-OST-5 enzyme and [35S]PAPS. As shown in Figure 2B, 
we observed an elevated level of endocytosis for 35S-labeled 
heparin in cells expressing Stab receptors when compared 
with cells expressing the empty vector. Stab1, the weakest re-
ceptor for heparin, bound heparin at a level slightly above 
that of the negative control (empty vector cells). Two Stab2 
isoforms (190-HARE and 315-HARE) displayed significantly 
higher levels of internalization of heparin than the negative 
control (Figure 2B). 
Structural Requirement for HS Endocytosis — HS contains 
various types of sulfations and GlcA versus IdoA residues. To 
understand the structural selectivity for binding to the Sta-
bilin receptors, we chemoenzymatically produced a series of 
HS polysaccharides with specific modifications ranging from 
N-sulfation alone on the glucosamine residue (construct 1) to 
the much more complex sulfation patterns commonly found 
in heparin and HS (constructs 8 and 9) (Table 1 and Figure 1). 
We observed that the polysaccharides carrying N-sulfation 
only or a combination of N-sulfation and a single O-sulfation 
type display low internalization via the Stabilin receptors (Fig-
ure 3, constructs 1-5). Increasing the O-sulfation types (or com-
bining N-sulfation with 2-O- and 6-O-sulfation) elevated the 
internalization via the Stabilin receptors (Figure 3, constructs 
6 and 7). Interestingly, the addition of 3-O-sulfation showed 
the highest internalization rate (Figure 3, constructs 8 and 9). 
Given the fact that 3-O-sulfation represents a rare modification 
in HS (28), our results suggest that Stabilin receptors recognize 
unique sulfation patterns independent of the charge density. 
This conclusion was further strengthened by the competitive 
inhibition using antithrombin (see Figure 5) as well as by em-
ploying the oligosaccharide substrates as described below (see 
Figure 7). Constructs 6 and 8 (with IdoA residues) and 7 and 
9 (without IdoA residues) exhibited similar binding to the re-
ceptors, suggesting that the presence of IdoA has no signifi-
cant effect on endocytosis. 
We also examined the direct binding between the polysac-
charide constructs and different Stabilin receptor ectodomains 
(Figure 4). The Stabilin receptors were captured from the me-
dium of cells secreting the corresponding receptor (Figure 4A) 
using anti-V5 antibody coupled to Sepharose resin and exposed 
to 35S-labeled HS constructs. As anticipated, a similar trend was 
observed for direct binding, namely that higher sulfation lev-
els for a given construct lead to greater binding to the Stabilin 
receptors (Figure 4, B–D). In these experiments, the empty vec-
tor negative control was used as a baseline for nonspecific poly-
saccharide binding due to the inherent “stickiness” of the high 
charge on the HS to the antibody resin. Again, the polysaccha-
rides carrying 3-O-sulfation (constructs 8 and 9) exhibited the 
highest binding toward the Stabilin receptors. We also observed 
that the binding levels of 8 and 9 to the 190-HARE and Stab1 
receptors were comparable, suggesting that the receptor makes 
no distinction between IdoA and GlcA (Figure 4, B and D). Al-
though slightly higher binding was observed for construct 9 
with 315-HARE (Figure 4C), we cannot conclude that IdoA de-
creases the binding of HS to the receptor. 
Antithrombin III Competes with Stabilins for HS Bind-
ing — ATIII is a serine protease inhibitor that regulates blood 
coagulation by targeting thrombin and factor Xa (29). Inhi-
bition of these targets occurs via the formation of a 1:1 com-
plex between ATIII and HS that contains a specific heparin 
pentasaccharide sequence for ATIII binding (30, 31). The 3-O-
sulfated glucosamine residue within the pentasaccharide is 
the last modification step during heparin biosynthesis and is 
carried out by 3-OST-1 (32). Because the 3-O-sulfated poly-
saccharides exhibited increased Stabilin-mediated endocy-
tosis, we asked whether Stabilin and ATIII bind to the same 
site in HS. First, we demonstrated the inhibition of [35S]hepa-
rin endocytosis with Stab1 cells in the presence of increasing 
concentrations of ATIII (Figure 5A). We utilized both ATIII-
binding polysaccharide constructs, constructs 8 and 9 con-
taining the 3-O-sulfation, and ATIII-nonbinding polysaccha-
ride constructs, constructs 6 and 7. As expected, constructs 
6-9 displayed distinct Stabilin-mediated internalization ef-
fects in the presence and absence of ATIII. ATIII did not in-
terfere with the endocytosis of constructs 6 and 7 in all three 
Figure 2. Internalization of 3-O-sulfated heparin via Stab1 and Stab2. 
A, cell lysates (20 μg) were separated by 5% SDS-PAGE, blotted to nitro-
cellulose, and probed with anti-V5 antibody. Lane 1, Stab2/190-HARE; 
lane 2, Stab2/315-HARE; lane 3, Stab1. B, stable cell lines expressing 
Stab1 (white bar), both Stab2 isoforms (gray bars), and empty vector (EV, 
black bar) were incubated with 35S-labeled 3-O-sulfated heparin for 3 h. 
The dotted line represents nonspecific binding values and is subtracted 
from the data to determine receptor-specific endocytosis. Endocytosis 
was evaluated by cpm/μg of cell lysate protein for each cell line, mean 
± S.D., n = 3. 
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cell lines (Figure 5, B and C). In contrast, endocytosis of con-
structs 8 and 9 was significantly decreased, but not entirely 
inhibited, in all three cell lines (Figure 5, D and E). It is also 
interesting to note that there is a significant amount of inter-
nalization of 35S-polysaccharide after ATIII inhibition (con-
structs 8 and 9). The internalization levels that could not be 
inhibited by ATIII for constructs 8 and 9 were similar to the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ones observed for constructs 6 and 7. These data suggest that 
ATIII and membrane-bound Stabilin receptors bind to the 
same site in HS for internalization. Our data also suggest that 
Stabs bind to HS in two modes. One mode is that it binds 
to the site that also interacts with ATIII, which may be the 
more significant interaction site; another mode is that it binds 
to highly negatively charged polysaccharides without struc-
tural selectivity. 
The Size of the Saccharide Versus Endocytosis in Stab1 and 
Stab2 Cell Lines — We next investigated the length of hepa-
rin required for endocytosis. First, we used heparin oligosac-
charides of different lengths ranging from a 10-mer to a 19-mer 
(constructs 14-23). None of these oligosaccharides were taken 
up by the empty vector cells including those without IdoA res-
idues (data not shown). Next, we tested all of the constructs 14-
23 with both Stab1 and Stab2 (315-HARE) cell lines. As summa-
rized in Figure 6B, both the 7-mer (11) and 8-mer (12) exhibit 
very little endocytosis, but endocytosis is slightly increased in 
the 9-mer (13b), especially for the Stab1 cells. The biggest jump 
in the incidence of endocytosis occurs when one additional 
sugar is added to make a 10-mer (15b). The amount of internal-
ized oligosaccharides remained steady up to a nonadecasaccha-
ride (19-mer, 23). From these data, the minimal size for signifi-
cant endocytosis is a 10-mer for both Stab1 and Stab2 receptors. 
Similar results were observed for the 190-HARE receptor. 
We next compared the internalization of the 7-mer (11) and 
19-mer (23) for internalization in full-length Stab1 and Stab2 
cell lines. We did not observe any internalization of the 7-mer 
in cells expressing either Stab1 (white bars) or Stab2/315-HARE 
(gray bars) (Figure 6B). Furthermore, we did not observe a sig-
Figure 4. Direct binding of HS oligosaccharides with Stab1 and Stab2 ectodomains. Ectodomains/secreted versions of each receptor were immunopu-
rified by V5 resin and were either subject to 5% SDS-PAGE, blotted, and probed with anti-V5 antibody (Lane 1, s190-HARE/Stab2; lane 2, s315-HARE/
Stab2; lane 3, sStab1) (A) or incubated with an equal amount of each HS construct for 1.5 h under rotation (B–D). The resin was washed with Tris-buff-
ered saline three times and then mixed with scintillation mixture, and cpm was determined. Counts per minute were normalized to the amount of pro-
tein on the resin. 
Figure 3. Modifications of heparosan determine internalization rates. 
The empty vector (EV, black bars), Stab1 (white bars), and Stab2/190-
HARE (gray bars) cell lines were incubated with equal amounts of each 
modified HS construct for 3 h. The cells were then washed, and the ly-
sates were counted by scintillation autoradiography. The amounts of 
[35S]HS constructs were determined by specific cpm/μg of protein cell 
lysate, mean ± S.D., n = 3. 
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nificant decrease in the internalization of the 19-mer (23) by 
competition with the synthetic pentasaccharide, Arixtra, at 50-
fold molar excess. These results demonstrate that the minimal 
length of a heparin oligosaccharide cleared by these cell lines 
is at least 10 sugars in length and that the synthetic pentasac-
charide is not cleared by cells expressing the Stabilin receptors. 
3-O-Sulfation Is Required for Decasaccharides to Bind to 
Stab Receptors and for Endocytosis — To further establish the 
role of 3-O-sulfation and the size requirement for the binding 
to Stab receptors, we utilized a series of oligosaccharides with 
and without 3-O-sulfation. These experiments also utilized la-
beled heparin as a positive control (black bars) and a structur-
ally defined heptasaccharide (7-mer, 11) (24) as a negative con-
trol. Both the Stab1 (Figure 7A) and the Stab2 (Figure 7B) cells 
show robust endocytosis with heparin and no endocytosis 
with 11. The oligosaccharides composed of eight or nine sug-
ars without 3-O-sulfation (12a and 13a) did not show endocy-
tosis in contrast to their 3-O-sulfated counterparts that exhib-
ited marginal to very low endocytosis (12b and 13b, Figure 
7, gray bars). This is in contrast with the 3-O-sulfated decasa-
ccharide (15b) and dodecasaccharide (17b), which exhibit ro-
bust endocytosis with the dodecasaccharide that is almost 
comparable with the heparin control (Figure 7, A and B). Fur-
thermore, the deca- and dodecasaccharide without 3-O-sulfa-
tion (15a and 17a, white bars) were not internalized near the ex-
tent as their sulfated counterparts (gray bars). Taken together, 
our data are consistent with the conclusions that 3-O-sulfation 
plays a significant role in binding to Stab receptors in the en-
docytosis of heparin and that the minimum size for binding to 
the Stab receptors is a decasaccharide. 
Figure 5. ATIII significantly inhibits Stabilin-mediated heparin endocytosis. A, a dose-response curve for ATIII against heparin was generated by incu-
bating Stab1 cells with labeled heparin and varying amounts of ATIII. At each concentration, cells were processed as described under “Experimental 
Procedures.” The dotted line represents the threshold for nonspecific binding. B–E, an equal amount of each construct (6-9) was preincubated with en-
docytosis medium (gray bars) or endocytosis medium supplemented with 0.2 mg/ml ATIII (white bars) and then added to each indicated cell line. Af-
ter 3 h, cells were washed, and radioactivity and protein contents were determined as specific cpm/μg of protein, mean ± S.D., n = 4. For constructs 8 
and 9 (D and E), the statistical differences in internalization in the presence or absence of ATIII were p ≤ 0.05 for all cell lines in contrast to constructs 
6 and 7 (B and C), which showed no significant difference. 3-O sulf., 3-O-sulfation. 
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3-O-Sulfated Decasaccharide Retention in Liver Is Similar 
to Heparin — It is known that UFH is retained by liver to dis-
play a fast clearance rate, whereas Fondaparinux (a pentasac-
charide) is not and displays a slow clearance rate in vivo (33). 
Therefore, these size and sulfation parameters should hold 
true if the Stabilin receptors are responsible for the bulk clear-
ance of systemic heparin. To test this, we individually injected 
mice via the tail vein with four 35S-labeled constructs: hepa-
rin (positive control); 7-mer (21, negative control); the decasa-
ccharide without 3-O-sulfation (12a); and the decasaccharide 
with 3-O-sulfation (12b) (Figure 8). Mice under general anes-
thesia were injected with equal amounts of radioactive mate-
rial that was allowed to circulate; the mice were then bled out, 
and the livers were collected and processed for scintillation 
counting. We found that the 7-mer (21, white bar) was not re-
tained in the liver. The decasaccharide with 3-O-sulfation (12b, 
dark gray bar) was retained in the liver to a similar degree as 
heparin (black bar). In contrast, the retention of the decasaccha-
ride without 3-O-sulfation (12a) in the liver was significantly 
reduced. To this end, our data suggest that the 3-O-sulfation 
contributed to the retention in liver in vivo. 
Discussion
Understanding the clearance rate of heparin has signif-
icant clinical implications for improving the safety of hep-
arin-based drugs. For surgical applications, a fast-clear-
ing heparin drug is preferred, allowing the anticoagulant 
effect to rapidly disappear after the operation and thus re-
ducing the risk for bleeding side effects. In contrast, a slow-
clearing heparin is more desirable for patients with ongoing 
use, avoiding repetitive dosing. Indeed, UFH is widely used 
in surgical procedures and kidney dialysis, whereas LMWH 
and Fondaparinux are more commonly used as prophylactic 
agents among high risk patients prone to thrombosis (34, 35). 
Although it is known that the size of the heparin chain plays 
a role in the rate of clearance in patients, the precise struc-
tural requirements for regulating clearance remain unchar-
acterized. Previous studies have demonstrated that a liver 
endothelial cell receptor, known as Stab, is primarily respon-
sible for heparin clearance (5). By taking advantage of our 
recent success in synthesizing heparins (22, 24), we investi-
gated the contribution of the sulfation and the size of hep-
arin to the binding to Stab proteins. Our results provide a 
Figure 6. Size of oligosaccharide affects endocytic rates. A, Both Stab1 
and Stab2/315-HAREcell lines were incubated with the 7-mer (11), 8-mer 
(12b), 9-mer (13b), 10-mer (15b), 15-mer (19), and 19-mer (23) for 3 
h. All cell lines were washed with Hanks’ buffered saline solution fol-
lowed by determination of cpm by scintillation counting and protein by 
the Bradford assay; mean ± S.D., n = 5. B, both radiolabeled 7-mer and 
19-mer oligosaccharides were incubated for 3 h with Stab1 cells (white 
bars) and Stab2/315-HARE cells (gray bars). To confirm that the short syn-
thetic pentasaccharide does not bind with any of the Stabilin receptors, 
we added a 50-fold excess clinical grade Arixtra (Ax) to the endocyto-
sis medium to both the 19-mer (black bars) and the 7-mer (not shown). 
After a 3-h incubation for all samples, the cells were washed and lysed, 
and radioactivity and protein were determined, mean ± S.D., n = 3. The 
Stab2/190-HARE cell lines showed similar results (data not shown). 
Figure 7. The 3-O-sulfated decasaccharide is the minimal size and 
modification required for binding to the Stabilin receptors. Both Stab1 
(A) and Stab2/315-HARE (B) were incubated with heparin (positive con-
trol, black bar) and ultralow molecular weight heparin (7-mer, nega-
tive control), 3-O-sulfated oligosaccharides (12b, 13b, 15b, 17b; dark 
gray bars), and non-3-O-sulfated oligosaccharides (12a, 13a, 15a, 17a; 
white bars) for 3 h. Endocytosis of each oligonucleotide was confirmed 
by washing the cells with Hanks’ buffered saline solution and determin-
ing radioactivity and protein levels, mean ± S.D., n = 3. 
20782 pempe et al. in The Journal of Biological chemisTry, 287 (2012) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
molecular basis for designing synthetic heparins with de-
sired clearance rates for unique clinical applications. 
Our study reveals two binding modes between heparin and 
Stab proteins. In one binding mode, the heparin polysaccha-
ride binds to Stab1/2 nonspecifically; such binding requires a 
long polysaccharide chain. Another binding mode is specific, 
in which Stab proteins recognize a saccharide domain contain-
ing a 3-O-sulfo group. In the specific binding mode, a much 
shorter oligosaccharide is sufficient to display high affinity to 
Stabs. We also demonstrate that a 3-O-sulfated decasaccharide 
displays higher retention in the liver in mice when compared 
with its counterpart without 3-O-sulfation, suggesting that 
Stab binding affinity correlates to the clearance in vivo. 
Our data also suggest that Stab proteins recognize a unique 
saccharide sequence. Although we do not know the precise 
saccharide structure recognized by the Stabilin receptors at 
the present time, some overlaps between the Stab-binding se-
quence and ATIII-binding sequence exist. We know that 3-O-
sulfation is a critical modification for displaying high binding 
affinity to ATIII and for carrying anticoagulant activity (36). 
Further, competitive binding of the Stab receptors and ATIII 
to heparins was observed in this study. The mechanistic effect 
of 3-O-sulfation on the binding to the Stabilin receptors is cur-
rently unknown. We postulate that this effect is unlikely to be 
purely attributed to an increase in charge density because 3-O-
sulfation is a rare modification in HS (29). A recent study sug-
gests that 3-O-sulfation may affect the conformation of neigh-
boring IdoA2S residues to rearrange the positioning of sulfo 
groups (37). In addition, previous studies have shown that 
one natural highly sulfated chondroitin sulfate (CS-D) did not 
compete with heparin in contrast to other similar chondroitin 
sulfates (CS-B, CS-E) that demonstrated some degree of com-
petition, providing evidence that charge is not the only deter-
minant for heparin binding to the Stabilins (9). 
This is the first study demonstrating the structural selec-
tivity of heparin binding to Stab1. The Stab1 receptor is ex-
pressed in the liver sinusoidal endothelium as well as in alter-
natively activated macrophages (11) and other physiological 
niches (38) and may play a role in both systemic and localized 
clearance of heparinoid molecules. Activated macrophages 
may modulate the amount of dermatan sulfate in wound flu-
ids that promote FGF-2 activity (39, 40). It is possible that Stab 
1 plays a role in regulating the amount of anticoagulant HS in 
wound fluid. 
It should be noted that the rate of endocytosis also depends 
on the concentration of Stab receptors on the cell surface. The 
190-HARE Stab2 isoform always showed the highest increase 
in endocytosis because these cells produce more receptor per 
microgram of cell lysate than the other two cell lines. Not sur-
prisingly, the liver endothelial cells exhibit a much higher ra-
tio of 190/315-HARE Stab2 than the recombinant cell lines, 
which may account for the rapid uptake of heparin within the 
liver (41). The consistently lower internalization rate of hep-
arin in the Stab1 cells may be reflective of the amount of to-
tal surface receptor available to bind and internalize heparin, 
a lower binding affinity, or the unavailability to bind ligand 
due to the very short transient time on the cell surface. Others 
have reported the very short transient time of Stab1 on the cell 
surface (11, 42). In these experiments, we noticed a discrep-
ancy in binding versus endocytosis. Our in vitro binding assays 
by immunoprecipitation of the ectodomain of Stab1 revealed 
that the binding of the HS oligomers was qualitatively about 
as high as that of the Stab2 ectodomains. This contrasts with 
the cell-based assays and reveals that a combination of surface 
availability and rapid turnover, not binding affinity, may be 
responsible for lower endocytic rates in Stab1 cells. In addi-
tion, the expression of Stab receptors can be regulated by other 
cellular mechanisms. A genetic screen in which human umbil-
ical vein endothelial cells activated with VEGF revealed an in-
crease of Stab1 expression reveals that growth factors and cy-
tokines are able to alter endocytosis profiles of tissues (26). 
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Suppl. Fig. S1. ESI-MS analysis of pure N-sulfated oligosaccharides. A, 
octasaccharide, measured MW: 1592.5 ± 0.5. B, nonasaccharide, measured MW: 
1833.9 ± 0.8. C, decasaccharide, measured MW: 2009.9 ± 0.7. D, dodecasaccharide, 
measured MW: 2427.4 ± 0.5. 
 
Suppl. Fig. S2. DEAE-HPLC chromatograms of HS oligosaccharides. A, 
Octasaccharide (12a); B, Nonasaccharide (13a); C, Decasaccharide without 3-O-
sulfation (15a); D, Decasaccharide with 3-O-sulfation (15b); E, Dodecasaccharide 
without 3-O-sulfation (17a); F, Dodecasaccharide with 3-O-sulfation (17b).  Multiple or 
broad peaks indicates a mixture. 
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